Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)

@article{Buechler2001TherapyFP,
  title={Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)},
  author={Peter Buechler and Howard A. Reber and Manuela C. B{\"u}ckler and Mendel A. Roth and Markus W. B{\"u}chler and Helmut Friess and William H. Isacoff and Oscar Joe Hines},
  journal={Journal of Gastrointestinal Surgery},
  year={2001},
  volume={5},
  pages={139-146}
}
The HER2/neu oncogene is overexpressed in human pancreatic cancer, but the clinical significance of that overexpression is uncertain. In the present study we investigated the antitumor efficacy of Herceptin, a new recombinant humanized anti-HER2/neu antibody, which exhibits cytostatic activity on breast and prostate cancer cells that overexpress the HER2 oncogene. That antibody may retard tumor growth in certain patients with those diseases. We quantified HER2 expression in various human… CONTINUE READING